Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ClouDr Group Limited ( (HK:9955) ) has issued an update.
ClouDr Group Limited has entered a service cooperation agreement with JD Health to expand online sales and service channels for its products, including Remifemin. This collaboration leverages JD Health’s extensive platform resources and ClouDr’s expertise in chronic disease management, aiming to promote high-quality, cost-effective medications and improve patient experiences.
The most recent analyst rating on (HK:9955) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on ClouDr Group Limited stock, see the HK:9955 Stock Forecast page.
More about ClouDr Group Limited
ClouDr Group Limited operates in the healthcare industry, focusing on chronic disease management. The company offers a unique pipeline of products and expertise in patient-doctor management, aiming to enhance medication purchasing experiences and provide professional health management services.
Average Trading Volume: 1,675,774
Technical Sentiment Signal: Sell
Current Market Cap: HK$720.6M
For an in-depth examination of 9955 stock, go to TipRanks’ Overview page.